Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.80
Bid: 29.00
Ask: 30.70
Change: -0.90 (-2.93%)
Spread: 1.70 (5.862%)
Open: 28.80
High: 29.80
Low: 28.80
Prev. Close: 30.70
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DiaSpect Tm McKesson US distribution agreement

9 Aug 2018 07:00

RNS Number : 2695X
EKF Diagnostics Holdings PLC
09 August 2018
 

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

EKF Diagnostics Holdings plc

("EKF", the "Company")

 

DiaSpect Tm US distribution agreement with McKesson

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has signed a private label distribution agreement with McKesson Medical-Surgical Inc., an affiliate of McKesson Corporation - the Fortune Global 500 healthcare distribution specialist and one of the largest companies in the US by revenue - for the Company's hand-held reagent-free hemoglobin analyzer, the DiaSpect Tm.

 

The DiaSpect Tm is the world's fastest hemoglobin analyzer and will be branded in the US by McKesson under its own branded line, as the McKesson Consult® Hb analyzer.

 

The agreement follows US Food and Drug Administration 510(k) clearance and CLIA waiver by statute for the DiaSpect Tm in April 2018, approving the product for use in point of care and Certificate of Waiver settings. Sales of the McKesson Consult® Hb analyzer are expected following full launch in the autumn, 2018.

 

For more information on the DiaSpect Tm see: www.ekfdiagnostics.com/diaspect.html 

 

Commenting, Julian Baines, CEO of EKF, said:  

"As I said in April the US market is a key target for the DiaSpect Tm, which gives physicians access to an easy to use, accurate and portable hemoglobin measurement system able to deliver laboratory quality results at the point of care within seconds." 

 

"This agreement with McKesson allows us to offer this innovative technology to physicians and childcare specialists across the US through the market's leading and most established healthcare distribution player. We expect that this partnership will ultimately deliver significant value to shareholders."

 

 

Enquiries:

 

EKF Diagnostics Holdings plc 

www.ekfdiagnostics.com

Christopher Mills, Non-Executive Chairman

Tel: 029 2071 0570

Julian Baines, CEO 

Richard Evans, FD & COO

N+1 Singer (Nomad & Broker)

Tel: 020 7496 3000

Aubrey Powell / Shaun Dobson

Walbrook PR Limited

Tel: 020 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

About McKesson Medical-Surgical mms.mckesson.com

McKesson Medical-Surgical Inc. is an affiliate of the McKesson Corporation. McKesson Corporation, currently ranked 6th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson Medical-Surgical works with health systems, physician offices, extended care providers, in-home patients, labs, payers and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson Medical-Surgical helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services.

About EKF Diagnostics Holdings plc www.ekfdiagnostics.com

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRDDGDIRBGBGII
Date   Source Headline
30th Mar 20217:01 amRNSFinal Results
30th Mar 20217:00 amRNSTrading update & Expansion of supply agreement
10th Mar 202111:45 amRNSExecutive Performance Bonus
3rd Mar 20217:00 amRNSNotice of Results
19th Feb 20214:36 pmRNSPrice Monitoring Extension
22nd Jan 20214:41 pmRNSSecond Price Monitoring Extn
22nd Jan 20214:36 pmRNSPrice Monitoring Extension
12th Jan 20217:00 amRNSTrading Update
5th Jan 20213:37 pmRNSHolding(s) in Company
30th Dec 20205:56 pmRNSHolding(s) in Company
14th Dec 20207:00 amRNSApproval of dividend in specie
10th Dec 20201:09 pmRNSResult of General Meeting
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name
26th Nov 20207:01 amRNSHolding(s) in Company
26th Nov 20207:00 amRNSCOVID-SeroKlir - FDA Emergency Use Authorisation
26th Nov 20207:00 amRNSSale of shares in Renalytix AI plc
24th Nov 20207:00 amRNSUpdate on strategic investment in Trellus Health
9th Nov 20207:00 amRNSTrading update
28th Oct 20202:15 pmRNSRe-issued: EKF marketing & distribution agreement
28th Oct 20207:00 amRNSEKF & Kantaro partner to market antibody testing
26th Oct 20207:00 amRNSDividend confirmation
22nd Oct 20207:00 amRNSNew orders for COVID-19 sample collection kits
2nd Oct 20207:00 amRNSTrading update
1st Oct 20207:00 amRNSExercise of Options and Total Voting Rights
14th Sep 20206:14 pmRNSDividend Timetable Amendment
14th Sep 20207:00 amRNSHalf-year Report
10th Sep 202012:00 pmRNSNotice of Results
20th Aug 20207:00 amRNSStrategic investment
5th Aug 20207:01 amRNSExecutive Performance Bonus
5th Aug 20207:00 amRNSSupply contract for COVID19 sample collection kits
14th Jul 20207:00 amRNSUpdate on trading and COVID-19 related contract
24th Jun 20204:40 pmRNSSecond Price Monitoring Extn
24th Jun 20204:35 pmRNSPrice Monitoring Extension
12th Jun 20204:41 pmRNSSecond Price Monitoring Extn
12th Jun 20204:35 pmRNSPrice Monitoring Extension
10th Jun 20205:43 pmRNSResults of AGM
8th Jun 20204:41 pmRNSSecond Price Monitoring Extn
8th Jun 20204:36 pmRNSPrice Monitoring Extension
15th May 20207:00 amRNSUpdate on trading and COVID-19 related contract
7th May 20207:00 amRNSPosting of Annual Report & Accounts &Notice of AGM
6th May 202011:30 amRNSExercise of options and Total Voting Rights
5th May 20204:41 pmRNSSecond Price Monitoring Extn
5th May 20204:36 pmRNSPrice Monitoring Extension
5th May 20207:00 amRNSDistribution Agreement for Quo-Test HbA1c Analyzer
29th Apr 20207:00 amRNSUK contract for COVID-19 sample collection kits
28th Apr 20207:00 amRNSCOVID-19 related manufacturing capacity update
27th Apr 20207:00 amRNSUpdate on COVID-19 related manufacturing contract
7th Apr 20207:00 amRNSFinal Results
24th Mar 20207:00 amRNSDetailed trading review including COVID-19 update
20th Mar 20207:00 amRNSInvestor results briefing update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.